All In Biotech

Drug Trial Radar · NCT05755789

Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery

Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery: a Multicentre, Double-blind, Randomized Controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 2,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,000

Planned (sponsor's estimate)

Start

Jun 22, 2023

Primary completion

May 2025

Study completion Jun 2025

Sponsor

Lead sponsor
Poitiers University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this prospective, multicentre, double-blind, randomized clinical trial is to compare intermittent cefoxitin administration to loading bolus followed by continuous infusion for surgical antibiotic prophylaxis in colorectal surgery. The main objective is to demonstrate the superiority of a loading dose of cefoxitin followed by continuous infusion over standard of care boluses in reducing SSI within 30 days after colorectal surgery

Conditions

  • Antibiotic Prophylaxis
  • Colorectal Surgery

Interventions

  • Loading bolus of cefoxitinDrug

    Cefoxitin \[2g\] before incision

  • Intermittent cefoxitinDrug

    Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure

  • Continuous infusion of placeboDrug

    Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure

  • Continuous infusion of cefoxitinDrug

    Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure

  • Intermittent placeboDrug

    Additional bolus of placebo every 2 hours until the end of surgical closure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Surgical site infectionTime frame: within 30 days after surgery

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Angers

    Angers, France · Recruiting

  • Hopital privé Arras les Bonnettes

    Arras, France · Recruiting

  • CHU Caen

    Caen, France · Recruiting

  • CHU Clermont Ferrand

    Clermont-Ferrand, France · Recruiting

  • CHU Grenoble

    Grenoble, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Hospices Civils Lyon

    Lyon, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • CHRU Nancy

    Nancy, France · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • Hopital Européen Gorges Pompidou

    Paris, France · Recruiting

  • Clinique Mutualiste la Sagesse

    Rennes, France · Recruiting

  • Hôpital Privé Rennais Cesson Sevigné

    Rennes, France · Recruiting

  • CH St Brieuc

    Saint-Brieuc, France · Recruiting

  • CHU St Etienne

    Saint-Etienne, France · Recruiting

  • Hopitaux de Strasbourg

    Strasbourg, France · Recruiting

  • CHU Toulouse Rangueil

    Toulouse, France · Recruiting

  • CH Bretagne Atlantique vannes

    Vannes, France · Recruiting

  • Centre Hospitalier de Poitiers

    Poitiers, Vienne, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.